Amneal Acquires Kashiv BioSciences in $1.1B Deal to Ride $300 Billion Biosimilar Wave

Amneal is buying Kashiv BioSciences for up to $1.1 billion to become a global leader in affordable biosimilar drugs. Strong Q1 results beat expectations and 2026 guidance raised.